Brief: Heidelberg Pharma AG: Announces Updated Guidance

Heidelberg Pharma AG

18/06/2024 12:51

June 18 (Reuters) - Heidelberg Pharma AG  HPHA.DE :
    * EQS-ADHOC: HEIDELBERG PHARMA AG ANNOUNCES UPDATED GUIDANCE
    * EXPECTS FOR FINANCIAL YEAR 2024 SALES AND OTHER INCOME
BETWEEN
EUR 9.0 MILLION AND EUR 12.0 MILLION (PREVIOUSLY: EUR 11.0
MILLION TO EUR 15.0 MILLION)
    * REASON FOR LOWER SALES IS THAT EXPECTED SALES ARE LIKELY
TO BE
DELAYED DUE TO DEVELOPMENTS AT LICENSE PARTNERS
    * OPERATING EXPENSES WILL REMAIN BETWEEN EUR 36.0 MILLION
AND EUR
40.0 MILLION
    * BASED ON THESE ADJUSTMENTS, AN OPERATING RESULT (EBIT)
BETWEEN
EUR -25.5 MILLION AND EUR -29.5 MILLION IS EXPECTED (PREVIOUSLY:
EUR -23.5 MILLION TO EUR -27.5 MILLION)
    * FOR 2024, HEIDELBERG PHARMA ANTICIPATES CASH REQUIREMENTS
OF EUR
18.0 MILLION TO EUR 22.0 MILLION (PREVIOUSLY: EUR 28.0 MILLION
TO EUR 32.0 MILLION)
    * MONTHLY CASH CONSUMPTION IS EXPECTED TO RANGE BETWEEN EUR
1.5
MILLION AND EUR 1.8 MILLION PER MONTH (PREVIOUSLY: EUR 2.3
MILLION AND EUR 2.7 MILLION)
    * COMPANY'S FINANCING IS SECURED UNTIL MID-2025
    * TAKING INTO ACCOUNT A FURTHER EXPECTED PAYMENT OF USD 75.0
MILLION FROM HEALTHCARE ROYALTY, COMPANY ASSUMES THAT FINANCING
WILL BE AVAILABLE UNTIL END OF 2026

Source text for Eikon:  ID:nEQ447Z4na 
Further company coverage:  HPHA.DE 

 (Reporting by Berlin Newsroom)
 ((berlin.newsroom@thomsonreuters.com;))